Scholar Rock (SRRK) Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 SMA
Go back to Scholar Rock (SRRK) Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 SMA| (NASDAQ: SRRK) | Delayed: 49.19 +1.86 (3.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $47.33 | 52 Week High | $ | |||
| Open | $47.95 | 52 Week Low | $ | |||
| Day High | $49.83 | P/E | N/A | |||
| Day Low | $47.73 | EPS | $ | |||
| Volume | 2,140,287 | |||||
